
The zzso zzso inhibitor zzso increases zzso and zzso zzso We conducted a phase I trial of zzso + zzso in patients with advanced solid zzso 

zzso + zzso were administered every 2 zzso Based on zzso zzso zzso was given 3 h after zzso but before zzso Two maximum tolerated doses were determined, one with zzso administered over 1 zzso and one with zzso split as a zzso zzso followed by a zzso zzso 

A total of 74 patients were enrolled and 63 were zzso The zzso with zzso was zzso 80 zzso over 1 h or 35 zzso zzso + 35 zzso over 4 zzso zzso zzso were zzso fatigue, zzso and zzso Clinical activity included 2 partial responses in small zzso cancer and zzso cancer and 1 complete response in zzso zzso zzso disease was seen in 22 zzso zzso studies showed increasing zzso with increasing zzso zzso Clinical benefit was correlated with the presence of zzso zzso Of 25 patients with zzso cancer, 11 had as best response zzso for zzso m zzso 6 zzso range zzso zzso despite failing zzso zzso zzso 

Treatment with zzso and zzso is a safe and effective zzso zzso of zzso that enhance the effects of zzso can be zzso Clinical activity is encouraging and includes prolonged stable disease in patients with zzso zzso zzso 

